Shire Ends Patent War With Actavis, Watson Over ADHD Drug

Law360, New York (April 25, 2013, 7:10 PM EDT) -- A unit of pharmaceutical giant Shire PLC said Thursday that it had reached a settlement with Actavis Inc. and Watson Pharmaceuticals Inc., resolving all pending patent litigation over the companies' attempts to market generic versions of the attention deficit hyperactivity disorder drug Intuniv.

Under the terms of the settlement, Actavis and Watson acknowledge that their generics infringed two Shire patents for guanfacine hydrochloride extended-release tablets, sold under the Intuniv name, and that the two patents are both valid and enforceable.

In return, Actavis will receive a...
To view the full article, register now.